Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting

AIDS Research and Human Retroviruses

Volumn 26, Issue 2, 2010, Pages 139-148

  Siripassorn, Krittaecho ^a   Manosuthi, Weerawat ^a   Chottanapund, Suthat ^a   Pakdee, Aranya ^a   Sabaitae, Siriwan ^a   Prasithsirikul, Wisit ^a   Tunthanathip, Preecha ^a   Ruxrungtham, Kiat ^b  

^a Bamrasnaradura Infectious Diseases Institute   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; PANCREATITIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77149129329     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0125     Document Type: Article

References (40)

1. Riddler SA, Haubrich R, DiRienzo AG, et al.: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-2106.
2. Panel on Antiretroviral Guidelines for Adult and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. [Update 3 November 2008; cited 10 December 2008.] Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
3. 3 in Mexico. XVII International AIDS Conference, 3-8 August 2008, Mexico City, Maxico. Abstract TUAB0104.
4. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867-870.
5. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regens-berg L, and Maartens G: Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and viro-logic outcomes. Ann Intern Med 2007;146:564-573.
6. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, and Suwanagool S: Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: A 24-week study. J Med Assoc Thai 2004;87:760-767.
7. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piya-vong B, Chumpathat N, and Chantratita W: Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007;44:447-452.
8. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, et al.: High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A=E is predominant. J Int Assoc Physicians AIDS Care 2006;5:152-156.
9. Marconi VC, Sunpath H, Lu Z, et al.: Prevalence of HIV-1 drug resistance after failure of a first highly active anti-retroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46:1589-1597.
10. Sutthent R, Arworn D, Kaoriangudom S, et al.: HIV-1 drug resistance in Thailand: Before and after National Access to Antiretroviral Program. J Clin Virol 2005;34:272-276.
11. World Health Organization (WHO): Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2006 revision. [Updated 7 August 2006, cited 10 May 2009.] Available from http://www.who.int/hiv/pub/guidelines/adult/en/index.html.
12. BHIVA Writing Committee: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503.
13. Hammer SM, Eron JJ, Jr., Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300: 555-570.
14. Ruxrungtham K, Pedro RJ, Latiff GH, et al.: Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravir-ine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcrip-tase inhibitor-experienced patients: Study TMC125-C227. HIV Med 2008;9:883-896.
15. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, et al.: Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med 2007;8:529-535.
16. Pujades-Rodriguez M, O'Brien D, Humblet P, and Calmy A: Second-line antiretroviral therapy in resource-limited settings: The experience of Medecins Sans Frontieres. AIDS 2008;22:1305-1312.
17. Staszewski S, Babacan E, Stephan C, et al.: The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saqui-navir without additional antiretroviral therapy. J Antimicrob Chemother 2006;58:1024-1030.
18. Hellinger J, Morris A, Piscitelli S, et al.: Pilot study of saquinavir-SGC (Fortovase, SQV) 1000mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, WA. Abstract 451-W.
19. Manosuthi W, Sungkanuparph S, Ruxrungtham K, et al.: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2008;47:127-129.
20. Gathe J, Washington M, Mayberry C, Piot D, and Nemecek J: IMANI-1 TC3WP single drug HAART-proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV + ARV-naive patients-interim analysis of subjects completing final 48 week data. The XV International AIDS Conference, 11-16 July 200, Bangkok, Thailand. Abstract MoOrB1057.
21. Ebrahim O and Hill A: Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection. AIDS 2005;19:211-212.
22. Pulido F, Delgado R, Perez-Valero I, et al.: Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother 2008; 61:1359-1361.
23. Molto J, Santos JR, Negredo E, Miranda C, Videla S, and Clotet B: Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. J Antimicrob Che-mother 2007;60:436-439.
24. Nunes E, Oliveira M, and Almeida M: 48-week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/mL on HAART - the KalMo Study. XVI International AIDS Conference, 13-18 August 2006, Toronto, Canada. Abstract TUAB0103.
25. Pulido F, Arribas JR, Delgado R, et al.: Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-9.
26. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, and Boucher CA: HIV monotherapy with ritonavir-boosted protease inhibitors: A systematic review. AIDS 2009;23: 279-291.
27. Steigbigel RT, Cooper DA, Kumar PN, et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-354.
28. Madruga JV, Cahn P, Grinsztejn B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38.
29. Lazzarin A, Campbell T, Clotet B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
30. Gulick RM, Lalezari J, Goodrich J, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
31. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al.: Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse tran-scriptase inhibitors. AIDS 2003;17:1889-1896.
32. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008;16:62-68.
33. Standford HIVDB team: Stanford University HIV Drug Resistance Database. [Cited 30 June 2008.] Available from http://hivdb.stanford.edu/index.html.
34. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al.: Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: The recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008;91:1925-1935.
35. Humphreys EH, Hernandez LB, and Rutherford GW: Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev 2007: CD006517.
36. Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, and Fessel WJ: Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 2007; 21:1547-1554.
37. Loutfy M, Raboud J, Thompson C, et al.: Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin Trials 2003;4:301-310.
38. El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4+ countguided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
39. Weber R, Sabin CA, Friis-Moller N, et al.: Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006;166: 1632-1641.
40. Molina JM, Andrade-Villanueva J, Echevarria J, et al.: Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372:646-655.